Focused On-demand Library for Synaptonemal complex central element protein 1

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.

PARTNER
Receptor.AI
 
UPACC
Q8N0S2

UPID:
SYCE1_HUMAN

ALTERNATIVE NAMES:
Cancer/testis antigen 76

ALTERNATIVE UPACC:
Q8N0S2; B2RC80; Q9BWU3; Q9BWU4

BACKGROUND:
The Synaptonemal complex central element protein 1, alternatively named Cancer/testis antigen 76, is integral to the formation and function of synaptonemal complexes during meiotic prophase. This protein's requirement for SYCP1 for incorporation into the central element highlights its crucial role in the assembly, stabilization, and recombination processes of the synaptonemal complex.

THERAPEUTIC SIGNIFICANCE:
Given its critical function in reproductive biology and its association with diseases such as Premature ovarian failure 12 and Spermatogenic failure, 15, Synaptonemal complex central element protein 1 presents a promising avenue for the development of treatments targeting these fertility issues. Exploring the therapeutic potential of this protein could lead to breakthroughs in managing and possibly curing these conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 6 of 8789